Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 studyXinxin Cao, Daobin Zhou, Ya‐Min Tian et al.|EClinicalMedicine|2022Cited by 43
Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal CenterXin Li, Ken H. Young, Zijun Y. Xu‐Monette et al.|The American Journal of Surgical Pathology|2017Cited by 41
Richter transformation driven by Epstein–Barr virus reactivation during therapy‐related immunosuppression in chronic lymphocytic leukaemiaMaría J. García‐Barchino, José A. Martinez‐Climent, María Eugenia Sarasquete et al.|The Journal of Pathology|2018Cited by 37
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label studyLijuan Deng, Jun Zhu, Zhiming Li et al.|American Journal of Hematology|2023Cited by 18
Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic MalignanciesYuqin Song, Jun Zhu, Wei Xu et al.|Blood|2020Cited by 16